Palo Alto Investors LP Puma Biotechnology, Inc. Transaction History

Palo Alto Investors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $3.97 Million - $9.17 Million	-1,392,997 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $179,158 - $260,333	19,100 Added 1.39%	1,392,997 $13.5 Million
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $43,412 - $67,685	5,580 Added 0.41%	1,373,897 $14.1 Million
Q3 2020 Nov 16, 2020	BUY	$9.5 - $11.14 $231,990 - $272,038	24,420 Added 1.82%	1,368,317 $13.8 Million
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $366,384 - $692,001	-52,266 Reduced 3.74%	1,343,897 $14 Million
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $295,053 - $684,542	46,983 Added 3.48%	1,396,163 $11.8 Million
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $367,250 - $606,245	-56,500 Reduced 4.02%	1,349,180 $11.8 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $2.77 Million - $8.04 Million	224,900 Added 19.05%	1,405,680 $17.9 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $433,677 - $884,685	20,880 Added 1.8%	1,180,780 $45.8 Million
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $23.3 Million - $54.2 Million	1,159,900 New	1,159,900 $23.6 Million

101

29M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $136M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

Stay updated on Palo Alto Investors LP with notifications on news.